within Pharmacolibrary.Drugs.ATC.A;

model A11HA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.15,
    Cl             = 0.002,
    adminDuration  = 600,
    adminMass      = 30 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.00026000000000000003,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.005166666666666667,
    Tlag           = 840
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>A11HA04</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Riboflavin (vitamin B2) is a water-soluble vitamin used as a dietary supplement to prevent and treat riboflavin deficiency. It plays a key role as a coenzyme in metabolic processes, including energy production, and is important for growth, development, and cellular function. Riboflavin is approved for use as a nutritional supplement and is often included in multivitamin preparations.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters were reported in healthy adult volunteers after single oral dose administration.</p><h4>References</h4><ol><li><p>Zempleni, J, et al., &amp; McCormick, DB (1996). Pharmacokinetics of orally and intravenously administered riboflavin in healthy humans. <i>The American journal of clinical nutrition</i> 63(1) 54–66. DOI:<a href=\"https://doi.org/10.1093/ajcn/63.1.54\">10.1093/ajcn/63.1.54</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/8604671/\">https://pubmed.ncbi.nlm.nih.gov/8604671</a></p></li><li><p>Chungi, VS, et al., &amp; Shargel, L (1989). Pharmacokinetics of sulfasalazine metabolites in rats following concomitant oral administration of riboflavin. <i>Pharmaceutical research</i> 6(12) 1067–1072. DOI:<a href=\"https://doi.org/10.1023/a:1015938706685\">10.1023/a:1015938706685</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/2576130/\">https://pubmed.ncbi.nlm.nih.gov/2576130</a></p></li><li><p>Shen, H, et al., &amp; Sinz, M (2024). A Pilot Study To Assess the Suitability of Riboflavin As a Surrogate Marker of Breast Cancer Resistance Protein in Healthy Participants. <i>The Journal of pharmacology and experimental therapeutics</i> 390(2) 162–173. DOI:<a href=\"https://doi.org/10.1124/jpet.123.002015\">10.1124/jpet.123.002015</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38296646/\">https://pubmed.ncbi.nlm.nih.gov/38296646</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end A11HA04;
